Crinetics Pharmaceuticals, Inc.
NASDAQ Global SelectTotal Valuation
Crinetics Pharmaceuticals, Inc. carries a market capitalization of 8.98B, placing it among publicly traded companies globally. Its enterprise value stands at 2.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 8.98B |
| Enterprise Value | 2.80B |
Share Statistics
Crinetics Pharmaceuticals, Inc. currently has 105.77M shares outstanding.
| Shares Outstanding | 105.77M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 88.54, and the price-to-book ratio stands at 3.32.
| PE Ratio | N/A |
| PS Ratio | 88.54 |
| PB Ratio | 3.32 |
| P/TBV Ratio | 3.32 |
| P/FCF Ratio | -8.89 |
| P/OCF Ratio | -8.83 |
Enterprise Valuation
| EV / Sales | 66.41 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Crinetics Pharmaceuticals, Inc. maintains a current ratio of 15.57, meaning it holds 15.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 15.57 |
| Quick Ratio | 15.24 |
| Debt / Equity | 3.96 |
| Debt / EBITDA | -0.09 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -42.45 |
| Return on Assets (ROA) | -38.42 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.20 |
Stock Price Statistics
Crinetics Pharmaceuticals, Inc.'s stock has gained approximately 175.71615% over the past 52 weeks. The 50-day moving average sits at 63.78, while the 200-day moving average is 48.12.
| Beta (5Y) | N/A |
| 52-Week Price Change | 175.71615% |
| 50-Day Moving Average | 63.78 |
| 200-Day Moving Average | 48.12 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Crinetics Pharmaceuticals, Inc. generated 42.16M in revenue and converted that into -501.61M in net income, yielding earnings per share of -5.03. EBITDA reached -544.85M, while operating income came in at -549.09M.
| Revenue | 42.16M |
| Gross Profit | 35.50M |
| Operating Income | -549.09M |
| Pretax Income | -501.43M |
| Net Income | -501.61M |
| EBITDA | -544.85M |
| EBIT | -549.09M |
| Earnings Per Share (EPS) | -5.03 |
Balance Sheet
Crinetics Pharmaceuticals, Inc. holds 1.21B in cash and equivalents against 47.19M in total debt, resulting in a net debt position of -55.50M. Total book value stands at 1.19B, with working capital of 1.16B providing operational flexibility.
| Cash & Cash Equivalents | 1.21B |
| Total Debt | 47.19M |
| Net Debt | -55.50M |
| Equity (Book Value) | 1.19B |
| Book Value Per Share | 11.27 |
| Working Capital | 1.16B |
Cash Flow
Crinetics Pharmaceuticals, Inc. produced -422.51M in operating cash flow over the past twelve months. After subtracting -2.66M in capital expenditures, free cash flow totaled -425.18M - equivalent to -4.26 per share.
| Operating Cash Flow | -422.51M |
| Capital Expenditures | -2.66M |
| Free Cash Flow | -425.18M |
| FCF Per Share | -4.26 |
Margins
Crinetics Pharmaceuticals, Inc. operates with a gross margin of 99.16, reflecting its pricing power and cost economics. The operating margin of -1,302.52 and net profit margin of -1,189.88 provide insight into operational efficiency.
| Gross Margin | 99.16 |
| Operating Margin | -1,302.52 |
| Pretax Margin | -1,189.45 |
| Profit Margin | -1,189.88 |
| EBITDA Margin | -1,292.46 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -10.81 |
| FCF Yield | -11.25 |
Scores
Crinetics Pharmaceuticals, Inc. posts an Altman Z-Score of 16.23, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 16.23 |